De Novo Hypertension and Decline of Renal Function in a Young Woman with Systemic Lupus Erythematosus and Antiphospholipid Syndrome by Viana, H et al.
CMYKP
    357
 ABSTRACT
Antiphospholipid syndrome nephropathy and 
lupus nephritis have similar clinical and laboratory 
manifestations and achieving the accuracy of diag-
nosis required for correct treatment frequently neces-
sitates a kidney biopsy.
We report the case of a 29-year-old woman referred 
to the nephrology service for de novo hypertension, 
decline of renal function and proteinuria. She had had 
systemic lupus erythematosus and antiphospholipid 
syndrome since the age of 21 and was taking oral 
anticoagulation. Two weeks later, after treatment of 
hypertension and achievement of adequate coagula-
tion parameters, a percutaneous renal biopsy was 
performed. The biopsy revealed chronic lesions of 
focal cortical atrophy, arterial fibrous intimal hyper-
plasia and arterial thromboses, which are typical 
features of antiphospholipid syndrome nephropathy.
We describe the clinical manifestations and his-
topathology of antiphospholipid syndrome neph-
ropathy and review the literature on renal biopsy in 
patients receiving anticoagulation. 
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 INTRODUCTION
Although the renal manifestations of antiphos-
pholipid syndrome (APS) have received scant atten-
tion until recently, the kidney is probably a major 
target organ in this syndrome. Antiphospholipid 
antibodies are detected in 30-40% of patients with 
systemic lupus erythematosus (SLE) and APS will 
develop in nearly one third of these patients1. More-
over, the kidney is commonly involved in SLE, with 
60–80% of patients developing urine or renal func-
tion abnormalities at some time during their clinical 
course2.
APS nephropathy and lupus nephritis have similar 
clinical and laboratory manifestations and a kidney 
biopsy is frequently required for accurate diagnosis 
and correct treatment.
 CASE REPORT
A 29-year-old woman was referred to the nephrol-
ogy department for evaluation of declining renal 
function and proteinuria. Systemic lupus erythema-
tosus (SLE) and antiphospholipid syndrome (APS) 
had been diagnosed at the age of 21 years old. The 
diagnosis of APS had been established after she had 
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developed a left lower leg deep venous thrombosis. 
The lupus disease had cutaneous, articular and 
psychiatric involvement, without known renal mani-
festations. Over the next 8 years she had been 
treated with warfarin (INR target: 2-3), prednisolone 
(10 mg/day) and hydroxychloroquine (200 mg/day). 
She had some cutaneous and articular lupus relaps-
es needing temporary increases of prednisolone 
dose. There had been no further clinically evident 
thrombosis episodes. She had never been pregnant. 
Her records showed proteinuria (0.5 mg/24 hours) 
over the previous 2 years and an increase in serum 
creatinine from 0.9 to 1.3 mg/dl in the previous 3 
months.
She presented to the nephrologist with de novo 
hypertension (150/110 mmHg), cutaneous lesions 
(butterfly malar rash, alopecia, livedo reticularis and 
purpuric vasculitis of fingers, toes and nail folds) 
and musculoskeletal manifestations (arthralgia and 
arthritis of finger and toe joints).
Investigations showed: 1) positive antinuclear, 
double stranded DNA, anti Ro/SSA antibodies; 2) 
slightly low complement fractions: C3 (67.4 mg/dl; 
N: 75-140) and C4 (9.50 mg/dl; N: 10-34); 3) positive 
antiphospholipid antibody: Anticardiolipin antibody 
(>120 units GPL; N<12), Anti-B2 glycoprotein-I (>100 
units SGU; N<12) and Lupus anticoagulant (1.65 R; 
N: 0.8-1.2); 4) slight reduction in size of the right 
kidney (10.1 cm vs 11.3 cm), with bilateral normal 
echogenicity, and regular contours.
The patient’s anticoagulation status did not 
allow immediate kidney biopsy and she began 
mycophenolate mofetil (500 mg/day) and lisinopril 
(20 mg/day).
Two weeks later, warfarin was stopped and low 
molecular weight heparin (LMWH) introduced 
(interrupted 24 hours before biopsy). With normo-
tension and adequate coagulation parameters (PT, 
PTT, platelet count, anti-Xa activity), a percutane-
ous renal biopsy was performed using a semi-
automated device with real time ultrasonic guid-
ance. In the absence of biopsy complication, LMWH 
was restarted after 48 hours, and warfarin one 
week later.
The kidney histology revealed a cortical specimen 
with 50 glomeruli: 25 glomeruli showed ischaemic 
retraction of the tuft – some with a pseudocystic 
appearance (Fig. 1); 10 were globally sclerosed by 
ischaemia and 15 were normal. Focal zones of atro-
phy were present in the subcapsular area, where 5 
of the 10 sclerosed glomeruli were seen, and in the 
deep cortex (Fig. 2). The ischaemic and sclerotic 
alterations described were mainly in these zones, 
where some infiltration by mononuclear inflamma-
tory cells could be observed. Many vessels (arterioles 
and medium interlobular arteries) were patent but 
organised thrombi filled the lumens of 2 medium-
Figure 1
Retracted ischaemic glomerular tuft forming pseudocystic lesions. Magni-
fication 250X, Silver stain.
Figure 2
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sized vessels (Figures 3 and 4). Some intimal hyper-
plasia could be seen in 2 further vessels. Vascular 
lesions were located exclusively in atrophic and 
fibrotic areas. Immunofluorescence revealed 8 glom-
eruli with IgM segmental deposits (++/+++). There 
was no deposition of IgG, IgA, C3, C4, C1q and fibrin 
in the glomeruli or in other parenchymal structures. 
The histological diagnosis was APS nephropathy so 
the warfarin dose was increased to obtain an INR 
around 3.5 and immunosuppressive therapy was not 
changed.
At present, 6 months later, the patient is in 
clinical remission from lupus and has stable renal 
function.
 DISCUSSION
The renal manifestations of APS result from 
thrombosis occurring at any location within the renal 
vasculature, that is, in the renal arterial trunk or 
branches, intraparenchymal arteries and arterioles, 
glomerular capillaries, and renal veins. APS neph-
ropathy (APSN) describes the parenchymal renal 
lesions following intrarenal thrombosis. Proven 
intrarenal thromboses, once other conditions result-
ing in similar renal lesions are excluded, have 
recently been included in the Classification Criteria 
for APS3. Daugas and colleagues4 studied the fre-
quency and clinical relevance of APSN in lupus 
patients. This retrospective study showed that APSN 
was present in 32% of the patients with SLE, in 
addition to, or independent of, lupus nephritis.
The more frequent clinical renal manifestations of 
APSN and lupus nephritis are proteinuria (ranging 
from mild to nephrotic), haematuria, hypertension 
(often severe) and acute or chronic renal insuffi-
ciency.
The literature reveals that patients with APSN 
have a high frequency of hypertension and elevated 
serum creatinine levels at the time of kidney biopsy5. 
Hypertension was one of the first major features 
described in association with livedo reticularis and 
APS6. Patients with APS complicated by hyperten-
sion should be vigorously investigated for an under-
lying renal lesion, especially in the presence of 
livedo reticularis7. Thus, renal involvement should 
be considered in any patient suffering from APS and 
hypertension, regardless of whether it is accompa-
nied by renal insufficiency, proteinuria, or haematu-
ria8. The pathophysiology of hypertension in the context 
of APS includes thrombosis/occlusion of the trunk 
of a renal artery leading to renovascular hyperten-
sion as well as stimulation of the renin-angiotensin-
aldosterone system secondary to intrarenal vascular 
lesions9.
APSN is a vaso-occlusive process associated with 
acute intrarenal thromboses and chronic vascular 
Figure 3
Fibrous organised thrombi and fibrous intimal hyperplasia in medium-
calibre artery. Magnification 250X, Periodic acid-shiff stain.
Figure 4
Fibrous thrombi filling lumen of medium-sized artery and ischaemic glom-
eruli. Magnification 160X, Silver stain.
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lesions. The acute manifestations are the result of 
thrombotic microangiopathy (TMA). However, chronic 
vascular changes of APSN are more frequent than 
acute events, but have received little attention until 
recently. They are characterised by arterial fibrous 
intimal hyperplasia (FIH), arteriosclerosis and organised 
thrombosis with or without recanalisation. The throm-
bosis progresses to fibrous occlusion of vessels and 
lead to focal cortical atrophy (FCA) in the region served 
by the involved vessels, often including subcapsular 
areas8. Progression of acute thrombotic lesions to 
chronic proliferative, obstructive and fibrotic forms may 
occur, as observed by Tektonidou and colleagues 10.
Thrombosis of parenchymatous vessels results in 
focal ischaemia and/or necrosis with corresponding 
reduction in kidney size or areas of cortical infarction 
on ultrasound or DMSA scanning11.
Our case demonstrates that accurate assessment 
of the relative contributions of APSN and lupus 
nephritis may only be possible with a renal biopsy. 
Histological examination is fundamental for diagnosis 
and therapeutic decision that is immunosuppression 
and/or anticoagulation, and the amount of each. 
Ultrasound-guidance and the use of semi-automated 
devices have made renal biopsy safe and reliable12. 
However, in patients on chronic anticoagulation 
two main problems must be considered: the risk of 
thrombosis if treatment is stopped versus the risk 
of bleeding after biopsy if anticoagulation is main-
tained. APS patients are classified as high risk for 
thromboembolism, and are usually considered to 
require “bridging” anticoagulation13 if oral antico-
agulation is stopped. 
Presently, there is no good evidence, nor clear 
consensus, for the management of patients receiving 
long-term oral anticoagulant therapy who need renal 
biopsy. The available data refers to experience with 
patients submitted to surgery. 
In the general population and in perioperative 
experience, the use of LMWH seems to be safer, more 
effective, simpler and less costly for short-term bridg-
ing therapy than unfractionated heparin14. However, 
if LMWH is used in patients with creatinine clearance 
< 40 ml/min, the anticoagulant effect of LMWH should 
be measured with an anti-factor Xa level 4 hours 
after LMWH administration, with a targeted therapeu-
tic anti-factor Xa level of 0.5-1.5 U/ml10. 
Jaffer et al.13 counsel about general patients and 
in perioperative cases: 1) to stop warfarin 5 days 
before; 2) to start LMWH 36 hours after the last war-
farin dose; 3) to give the last dose of LMWH approx-
imately 24 hours before; 4) to restart LMWH 24 hours 
after the procedure if there is no contraindication; 5) 
to restart warfarin 24 hours later; 6) to discontinue 
LMWH when INR is 2-3 for 2 consecutive days.
In nephrology, the data are lacking and some 
nephrologists preferred unfractionated heparin for 
all patients or in cases of reduced renal function. 
The timing of warfarin restarting is also debatable. 
In our experience, we use the following scheme 
with satisfactory results: 1) stop warfarin 5-7 days 
before renal biopsy; 2) introduced low molecular 
weight heparin (LMWH) when INR<2; 3) interrupt 
LMWH 24 hours before biopsy; 4) evaluate/correct 
coagulation parameters (PT, PTT, platelet count, anti-
Xa activity) and haemoglobin level in biopsy day; 5) 
evaluate/optimise arterial pressure; 6) perform per-
cutaneous renal biopsy using a semi-automated 
device with real time ultrasonic guidance; 7) restart 
LMWH after 48 hours in the absence of biopsy com-
plication; 8) restart warfarin 5-7 days later.
The intensity of long-term oral anticoagulation 
required for APS patients has been debated15. Ran-
domised controlled trials have suggested that INR 
levels of 2.0-3.0 may be sufficient in uncomplicated 
APS patients with only venous thrombotic events. 
In patients with arterial events or with recurrent 
thrombotic events despite INR in this range, the 
anticoagulation intensity should probably be 
increased, with a target INR between 3.0 and 4.0.
 CONCLUSION
The clinical patterns of lupus nephritis and APSN are 
often similar. Biopsy is essential for an accurate diag-
nosis and institution of appropriate therapy. Even in 
anticoagulated patients, renal biopsy may be performed 
safely if appropriate peribiopsy measures are taken.
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